Longitudinal Study of a Human Drug-Induced Model of Autoantibody to Cytoplasmic Rods/Rings following HCV Therapy with Ribavirin and Interferon-α

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Keppeke, Gerson Dierley ^a   Nunes, Eunice ^a   Ferraz, Maria Lucia Gomes ^a   Silva, Eduardo Antônio Benedito ^a   Granato, Celso ^a,b   Chan, Edward K L ^c   Andrade, Luís Eduardo C ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Fleury   (Brazil)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CYTOPLASMIC RODS AND RINGS AUTOANTIBODY; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; EXPERIMENTAL MODEL; FEMALE; FOLLOW UP; GENOTYPE; HEP 2 CELL; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; AUTOANTIBODIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 84866666932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045392     Document Type: Article

References (58)

1. Illei GG, Tackey E, Lapteva L, Lipsky PE, (2004) Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 50: 1709-1720.
2. Tan EM, (1982) Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 33: 167-240.
3. Satoh M, Vazquez-Del Mercado M, Chan EKL, (2009) Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. Mod Rheumatol 19: 219-228.
4. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, et al. (2012) Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 64: 2319-2327.
5. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, et al. (2011) Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63: 191-200.
6. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, et al. (1997) Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40: 1601-1611.
7. Muratori P, Muratori L, Stroffolini T, Pappas G, Terlizzi P, et al. (2003) Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. Clin Exp Immunol 131: 118-121.
8. Narciso-Schiavon JL, Freire FC, Suarez MM, Ferrari MV, Scanhola GQ, et al. (2009) Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 21: 440-446.
9. Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL, (2009) Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat 16: 325-331.
10. Yee LJ, Kelleher P, Goldin RD, Marshall S, Thomas HC, et al. (2004) Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 11: 459-464.
11. Chen CH, Lee CM, Hu TH, Wang JH, Hung CH, et al. (2010) Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. Chang Gung Med J 33: 258-265.
12. Zusinaite E, Metskula K, Salupere R, (2005) Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J Gastroenterol 11: 488-491.
13. Dalekos GN, Zachou K, Liaskos C, Gatselis N, (2002) Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview. Eur J Intern Med 13: 293-303.
14. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, et al. (1999) International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 31: 929-938.
15. Muratori P, Muratori L, Agostinelli D, Pappas G, Veronesi L, et al. (2002) Smooth muscle antibodies and type 1 autoimmune hepatitis. Autoimmunity 35: 497-500.
16. Bottazzo GF, Florin-Christensen A, Fairfax A, Swana G, Doniach D, et al. (1976) Classification of smooth muscle autoantibodies detected by immunofluorescence. J Clin Pathol 29: 403-410.
17. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, et al. (1994) Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 21: 199-203.
18. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, et al. (1995) Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 108: 1770-1777.
19. Himoto T, Murota M, Yoneyama H, Deguchi A, Kurokochi K, et al. (2010) Clinical characteristics of patients with autoimmune hepatitis seropositive for anticentromere antibody. Hepatol Res 40: 786-792.
20. Chan EKL, Carcamo W, Dhawan P, Satoh M, Liu C, et al. (2008) Cytoplasmic rings and rods - targets of emerging autoantibodies. Guadalajara, Jalisco, México.
21. Keppeke GD, Nunes E, Ferraz M, Granato C, Andrade LE (2010) Autoantibodies against novel cytoplasmic structures (Rods and Rings) are tightly associated with interferon therapy in hepatitis C patients. In: Hulek P, editor. Prague, Czech Republic. Foundation of the Czech Society of Hepatology. pp. 108.
22. Carcamo WC, Yao B, Satoh M, Reeves WH, Liu C, et al. (2009) Cytoplasmic rings/rods as autoimmune targets of emerging human autoantibodies associated with HCV virus infection and interferon therapy. In: Conrad K, Chan EKL, Fritzler MJ, Humbel RL, von Landenberg P, et al., editors. 9th Dresden Symposium on Autoantibodies. Dresden, Germany: Pabst Science Publishers. pp. 127-134.
23. Carcamo WC, Satoh M, Kasahara H, Terada N, Hamazaki T, et al. (2011) Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. PLoS One 6: e29690.
24. Seelig HP, Appelhans H, Bauer O, Bluthner M, Hartung K, et al. (2011) Autoantibodies against inosine-5′-monophosphate dehydrogenase 2-characteristics and prevalence in patients with HCV-infection. Clin Lab 57: 753-765.
25. Covini G, Carcamo WC, Bredi E, von Muhlen CA, Colombo M, et al. (2011) Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C. Antivir Ther.
26. Willingham MC, Richert ND, Rutherford AV, (1987) A novel fibrillar structure in cultured cells detected by a monoclonal antibody. Exp Cell Res 171: 284-295.
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-1277.
28. Hochberg MC, (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.
29. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23: 581-590.
30. Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, et al. (2001) Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. Arthritis Rheum 44: 735-736.
31. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127.
32. Bohan A, Peter JB, (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347.
33. Bohan A, Peter JB, (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292: 403-407.
34. Miller FW, Rider LG, Plotz PH, Isenberg DA, Oddis CV, (2003) Diagnostic criteria for polymyositis and dermatomyositis. Lancet 362: 1762-1763; author reply 1763.
35. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, et al. (2008) Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 48: 169-176.
36. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, et al. (1994) Genotypic analysis of hepatitis C virus in American patients. Hepatology 20: 1405-1411.
37. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, et al. (1995) Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med 122: 161-168.
38. Lopez-Labrador FX, Ampurdanes S, Forns X, Castells A, Saiz JC, et al. (1997) Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 27: 959-965.
39. Gale M Jr, (2003) Effector genes of interferon action against hepatitis C virus. Hepatology 37: 975-978.
40. Gilmour KC, Reich NC, (1995) Signal transduction and activation of gene transcription by interferons. Gene Expr 5: 1-18.
41. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC, (2004) Human interferons alpha, beta and omega. Growth Factors 22: 243-251.
42. Blight KJ, Kolykhalov AA, Rice CM, (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290: 1972-1974.
43. Zhu H, Zhao H, Collins CD, Eckenrode SE, Run Q, et al. (2003) Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 37: 1180-1188.
44. Guo JT, Sohn JA, Zhu Q, Seeger C, (2004) Mechanism of the interferon alpha response against hepatitis C virus replicons. Virology 325: 71-81.
45. Ronnblom L, Alm GV, (2001) An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22: 427-431.
46. Ronnblom L, Alm GV, (2003) Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 5: 68-75.
47. Markland W, McQuaid TJ, Jain J, Kwong AD, (2000) Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 44: 859-866.
48. Maag D, Castro C, Hong Z, Cameron CE, (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276: 46094-46098.
49. Bougie I, Bisaillon M, (2003) Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. J Biol Chem 278: 52471-52478.
50. Steinhauer DA, Domingo E, Holland JJ, (1992) Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122: 281-288.
51. Holland JJ, De La Torre JC, Steinhauer DA, (1992) RNA virus populations as quasispecies. Curr Top Microbiol Immunol 176: 1-20.
52. de Veer MJ, Holko M, Frevel M, Walker E, Der S, et al. (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69: 912-920.
53. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, et al. (2007) Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 46: 1548-1563.
54. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S, (2008) Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 28: 1332-1343.
55. Liu JL, (2010) Intracellular compartmentation of CTP synthase in Drosophila. J Genet Genomics 37: 281-296.
56. Liu JL, (2011) The enigmatic cytoophidium: compartmentation of CTP synthase via filament formation. Bioessays 33: 159-164.
57. Noree C, Sato BK, Broyer RM, Wilhelm JE, (2010) Identification of novel filament-forming proteins in Saccharomyces cerevisiae and Drosophila melanogaster. J Cell Biol 190: 541-551.
58. Ingerson-Mahar M, Briegel A, Werner JN, Jensen GJ, Gitai Z, (2010) The metabolic enzyme CTP synthase forms cytoskeletal filaments. Nat Cell Biol 12: 739-746.